Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AWARE-2 - Randomized Controlled Trial Ablation Strategy for Paroxysmal Atrial Fibrillation - Trigger and Substrate Guided Wide Area Radiofrequency Ablation Compared to Pulsed Field Ablation Pulmonary Vein Isolation

NCT04823299 is registered in ClinicalTrials.gov with Ottawa Heart Institute Research Corporation as lead sponsor.

NCT NCT04823299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04823299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AWARE-2 - Randomized Controlled Trial Ablation Strategy for Paroxysmal Atrial Fibrillation - Trigger and Substrate Guided Wide Area Radiofrequency Ablation Compared to Pulsed Field Ablation Pulmonary Vein Isolation
Lead sponsor
Ottawa Heart Institute Research Corporation
Phase
Not applicable
Overall status
Recruiting
Start date
March 23, 2026
Completion date
March 31, 2030
Enrollment
556 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, catheter ablation, radiofrequency catheter ablation